U.S. FDA approves Merck insomnia drug
WASHINGTON Aug 13 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co..
The drug, to be called Belsomra, is the first in a new class of sedatives that block chemicals in the brain called orexins that help keep people awake.
Belsomra, known generically as suvorexant, has the potential to cause next-day sleepiness and impaired driving.
- Exclusive: Iran seeks give and take on Islamic State militants, nuclear program
- Alibaba IPO ranks as world's biggest after additional shares sold
- Islamic State tells followers to attack U.S., French citizens: website
- Study of smoking cancer patients fuels e-cigarette debate
- Kurds say they have halted Islamic State advance on Syrian town |